Design of a multi-epitope vaccine against drug-resistant mycobacterium tuberculosis and mycobacterium bovis using reverse vaccinology

Simple item page
dc.contributor.authorAkurut, Eva
dc.contributor.authorGavamukulya, Yahaya
dc.contributor.authorMulindwa, Julius
dc.contributor.authorIsiagi, Moses
dc.contributor.authorGaliwango, Ronald
dc.contributor.authorBbuye, Mudarshiru
dc.contributor.authorLujumba, Ibra
dc.contributor.authorKiberu, Davis
dc.contributor.authorNabisubi, Patricia
dc.contributor.authorKebirungi, Grace
dc.contributor.authorKambugu, Andrew
dc.contributor.authorCastelnuovo, Barbara
dc.contributor.authorNkurunungi, Gyaviira
dc.contributor.authorJjingo, Daudi
dc.contributor.authorOketch, Brenda
dc.contributor.authorKateete, David Patrick
dc.contributor.authorMboowa, Gerald
dc.date.accessioned2025-10-07T14:29:48Z
dc.date.available2025-10-07T14:29:48Z
dc.date.issued2025
dc.descriptionArticle
dc.description.abstractThe global burden of Mycobacterium tuberculosis (M. tuberculosis) and Mycobacterium bovis (M. bovis), the rise of drug-resistant strains, necessitates an urgent need for developing more effective vaccines. This study employed an in-silico approach to design a multi-epitope vaccine targeting the PE_PGRS16 protein, a conserved virulence factor found across both species, including drug-resistant strains. PE_PGRS16 was chosen due to its extracellular localization, adhesion properties, and virulence characteristics, making it a promising vaccine target. Epitopes for B-cells, Cytotoxic T Lymphocytes, and Helper T Lymphocytes were selected based on antigenicity, non-toxicity, and immune response potential. The vaccine construct demonstrated favorable properties, including high antigenicity, solubility, and stability, with a low instability index (-31.31) and binding energy (-44.566) when docked to TLR4, suggesting its potential for immune activation. Griselimycin was incorporated as an adjuvant to enhance immunogenicity, as predicted by C-ImmSim simulations. Population coverage analysis for East Africa revealed high applicability, with 98.35% coverage for Class I epitopes, 100% coverage for Class II epitopes, and 100% combined coverage, with average hit values of 8.4, 12.26, and 20.66, respectively. These results suggest broad potential for global vaccine deployment. This study presents a novel multi-epitope vaccine targeting PE_PGRS16, with the potential to combat Mycobacterium tuberculosis and Mycobacterium bovis infections, including drug-resistant forms. Further experimental validation is necessary to confirm its efficacy and safety. Keywords Mycobacterium tuberculosis, Mycobacterium bovis, Vaccines, BCG, Reverse vaccinology, Molecular Docking, Tuberculosis, Drug resistance
dc.description.sponsorshipMakerere University : University of Cape Town: Medical Research Council : Busitema University
dc.identifier.citationAkurut, E., Gavamukulya, Y., Mulindwa, J., Isiagi, M., Galiwango, R., Bbuye, M., ... & Mboowa, G. (2025). Design of a multi-epitope vaccine against drug-resistant mycobacterium tuberculosis and mycobacterium bovis using reverse vaccinology. Scientific reports, 15(1), 27298.
dc.identifier.urihttps://doi.org/10.60682/ph2k-6549
dc.language.isoen
dc.publisherNature
dc.relation.ispartofseriesScientific Reports ; (2025) 15:27298
dc.titleDesign of a multi-epitope vaccine against drug-resistant mycobacterium tuberculosis and mycobacterium bovis using reverse vaccinology
dc.typeArticle
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
Department of Biochemistry & Molecular Biology